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Abstract
Obesity and hypothalamic GH deficiency contribute in
different ways to the disturbances of body composition
in Prader-Willi syndrome (PWS); while both increase the
fat compartment, the reduction of lean tissue mass has
been attributed mainly to GH deficiency. Therefore, body
composition measured by dual-energy X-ray absorp-
tiometry was prospectively studied in 12 overweight chil-
dren with PWS and weight for height (WfH) SDS 10
before and during 3.5 years of treatment with hGH (0.037
mg/kg/day) on average. In the long term, there is a net
reduction of body fat from 3.1 to 1.2 SD, with a minimum
at the end of the second year of treatment. WfH SDS cor-
rectly reflects body fat mass and its changes. The initial
deficit of lean mass (–1.6 SD) is counteracted by GH only
during the first year of therapy (increase to –1.25 SD). But
in the long term, GH therapy does not further compen-
sate for this deficit, when lean mass is corrected for its
growth-related increase. In conclusion, exogenous GH
changes the phenotype of children with PWS: fat mass
becomes normal, but, at least in the setting studied, GH
is not sufficient to normalize lean tissue mass.
Copyright © 2000 S. Karger AG, Basel
Introduction
Obesity is the growing epidemic of industrialized coun-
tries and there is no simple remedy, because it is the result
of a variety of underyling pathogenetic factors. Therefore,
rare monocausal syndromal forms of obesity, such as Pra-
der-Willi syndrome (PWS), are increasingly attractive
models to evaluate specific pathogenesis. With an esti-
mated incidence of 1:15,000, PWS remains the most fre-
quent form of genetic obesity. Its main features, namely
polyphagia, obesity, short stature, hypogonadism, muscle
hypotononia and mental retardation, are linked to a hypo-
thalamic dysfunction, which has not yet been comprehen-
sively described. Nevertheless, evidence increases that,
even though difficult to diagnose, there is a hypothalamic
GH deficiency accounting not only for short stature and
increased fat mass, but also for the decreased absolute lean
body mass [1] – in contrast to nonsyndromal obesity.
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Table 1. Clinical data of children with PWS
Patient
No. (n = 12)
Sex
(7 f, 5 m)
Agea
years
Pubertal
stagea, b B or G
Heighta
SDS
Weight for
heighta, SDS
Study period
months
F 3.70 1 –1.90 4.14 42
12 M 6.70 1 –0.60 3.00 24
13 F 5.00 1 –0.80 3.16 42
14 F 6.80 1 –2.08 6.38 42
15 M 6.80 1 –1.40 4.37 42
16 M 7.00 1 –1.60 4.34 42
17 F 7.10 1 –2.43 0.84 42
18 M 9.50 1 –2.10 3.76 42
19 F 11.10 2 –0.40 5.31 12
211 F 13.30 2–3 –4.31 4.31 12
222 M 13.50 3 –0.74 12.04 36
233 F 14.60 2–3 –4.82 1.57 42
Median 7.1 1 –1.75 4.23 42
Range 3.7 to 14.6 1 to 3 –4.82 to –0.4 0.84 to 12.04 12 to 42
Substitution: 1 With ethinylestradiol since age 14.5 years; 2 with testosterone 100 mg i.m. since age 14.8 years;
3 combination of estradiol/progesterone since age 16.6 years.
a Values at the beginning of therapy.
b Pubertal stage according to Tanner; B = breast stage in female and G = genital stage in male patients.
The reduced lean mass might contribute to muscle
hypotonia and decreased motor activity, thereby further
compounding obesity. Since the disturbance of body com-
position and its sequels are the main causes of morbidity
and mortality [2, 3], therapy should first aim at reducing
fat mass and, second, at increasing muscle mass. It has
been shown that these patients may benefit from the fat-
reducing and anabolic properties of GH [4–8], but the lon-
ger-term outcome of GH therapy is uncertain. We focussed
on whether fat mass is reduced in the long term. We further
wanted to quantify the initial muscle mass deficit and its
potential compensation during GH therapy.
The aim of the study was not to achieve normal height
in PWS, but height course was monitored to test suste-
nance of growth-anabolic GH effects; weight for height
(WfH) was evaluated to verify whether it is an easily
assessable clinical parameter correctly reflecting body fat
mass.
Patients and Methods
Twelve children with PWS, documented by deletion or uniparen-
tal disomy of chromosome 15, were studied prospectively (table 1).
The long-term effects of GH on growth [9] and the 1-year results of
physical performance and well-being have been published earlier
[6].
All children with PWS and overweight, defined as WfH standard
deviation score (SDS) 1 0, were included (table 1), 8 being prepuber-
tal and 4 pubertal (Tanner breast or genital stages 2 and 3). The chil-
dren not included with WfH ! 0 were all younger than 4 years. Miss-
ing values were not due to dropouts, but to uncompleted investiga-
tion intervals as a result of delayed start of therapy (missing at 42
months).
The children were treated with 24 IU/m2/week (F0.037 mg/kg/
day) recombinant hGH (Pharmacia & Upjohn, Dübendorf, Switzer-
land), administered in daily subcutaneous injections for 3.5 years on
average. The study has been approved by the Ethics Committee of
the Children’s University Hospital of Zürich and informed consent
was obtained by the parents. No additional medication was adminis-
tered besides sex steroids in 3 pubertal patients with hypogonadism
after the age of 14.5 years and after 18 months of GH therapy. The
patients were advised to continue their diets, adapted to the recom-
mendations of the Prader-Willi Syndrome Association of USA [10].
Food intake was monitored by records; in general, the energy intake
(median 11.3, range 8–13.4 kcal/cm height) was 20–40% less than
recommended for healthy children.
Height and WfH were assessed 6-monthly by the first author
according to standard techniques [11] and are given as SDS (individ-
ual value – reference mean divided by SD) to scale the data for com-
parison across ages and sex, using the First Zürich Longitudinal
Study [11]. WfH was used instead of weight for age: In consideration
of the reduced initial height of untreated children with PWS and the
changes to be expected during GH therapy, this is the most adequate
representation of body mass.
Body composition was determined before therapy, and then after
6, 12, 24, 36 and 42 months in all children by dual-energy X-ray
absorptiometry (DEXA) (Hologic QDR-2000, Waltham, Mass.,
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Fig. 1. Height SDS in children with PWS
(prepubertal ), n = 8 and pubertal j, n = 4)
before and under up to 3.5 years of GH ther-
apy, as medians (solid lines) as well as mini-
mum and maximum of the combined group
(broken lines). Significant differences in the
combined group of prepubertal and pubertal
children versus the value before therapy are
indicated as * p ! 0.05, ** p ! 0.01.
Fig. 2. Weight for height SDS in children
with PWS, before and under up to 3.5 years
of GH therapy (symbols as in figure 1).
USA; software version 7.10B). Lean tissue mass (LTM) was calcu-
lated as fat-free mass minus bone mineral content. Lean and fat mass
were compared to two sets of reference data:
(1) Reference values measured with the same DEXA method, but
in a different population (in part published previously [12, 13]): Data
are given as SDSs based on prediction models established in female
(n = 412) and male (n = 479) Caucasian US American children cover-
ing the age range of 0.3–19 years, scanned in a Hologic QDR-2000
(pencil-beam mode, body composition software version 5.56). Var-
ious combinations of age and height, using fractional and integer
powers and log transformations, were tested for development of the
prediction model. The following model provided the best overall pre-
diction (lowest SEE) of LTM for the reference population:
ln (LTM) = a lnHt + b Age + c
with gender-dependent constants:
a = 1.836 or 1.995, b = 0.0327 or 0.0136,
c = 6.0811 or –6.7647 for males or females, respectively.
Using this model, the predicted values were calculated for each
gender, then grouped into 1-year age intervals, and the SD per age
group calculated. Since SD was not independent of age, we success-
fully established the following linear model:
SD (Age) = d Age + e, where d = 0.2163 or 0.1362,
e = 0.323 or 0.831, for males or females, respectively.
For each PWS subject, a predicted LTM was calculated based on
their age, gender, and height. The individual SD score was calculated
as:
SDS for LTM = (measured LTM – predicted LTM)/SD (Age).
SD scores for fat mass (FM) were calculated similarly:
SDS for FM = (observed fat – predicted fat)/SD,
whereby predicted fat was derived as a function of age only, since
height had little influence.
(2) Reference values measured with a different DEXA instru-
ment (Lunar DPXL), but in a similar European population: Lean
tissue and fat mass are calculated as SDS for sex and chronological
age (or height), using a cross-sectional study in Dutch children
14 years of age and with height 1100 cm as reference [14]. There-
fore, a relation to the healthy reference population was possible in
only 7 children of the 8 prepubertal children at the beginning of ther-
apy. We decided to compare our data with the Dutch population,
even though small systematic differences in the body composition
measurements are known among the DEXA instruments. However,
the linear regression between the results for the two DEXA methods
is high (r2 1 0.95) and not dependent on BMI [15, 16], hence these
systematic differences will not substantially alter the assessment of
our longitudinal data.
The relation of LTM exclusively to age could result in a false
underestimation, because children with PWS are short for age before
GH therapy [6]. Furthermore, we were interested to know whether
GH has an additional effect on LTM beyond its growth-related
increase. For these reasons, LTM was related to each reference group
not only correcting for age and sex, but also for height.
Statistical Methods
As weight and fat-related parameters showed a skew distribution,
all values are depicted as medians and ranges. The changes induced
by GH therapy after 6, 24, 36 and 42 months were tested by the
nonparametric Wilcoxon signed ranks test for paired samples, and p
values !0.05 were considered significant. Linear correlations were
tested by Spearman’s rank test. All data were processed by GAS 3.3
of the Institute for Medical Informatics (IMI, Zürich, Switzerland).
Results
Anthropometry
Before GH therapy was started, height was below the
normal mean in all patients. During the first 36 months of
GH therapy it continuously rose to the normal average in
prepubertal children (fig. 1), but less consistent changes of
height were observed in pubertal patients. WfH decreased
1 2
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Table 2. Body composition measured by DEXA in 12 overweight children with PWS before and during 3.5 years of GH therapy, compared to
two sets of reference data (see Methods)
Overweight PWS
children
Before therapy
mean range n
12 months’ GH therapy
mean range n p*
42 months’ GH therapy
mean range n p*
43.7 30.6 to 60.5 12 29.6 23.2 to 57.4 12 0.002 34.3 25.8 to 47.4 8 0.022
Fat SDS-US 2.2 –0.74 to 4.87 12 0.13 –2.43 to 6.23 12 0.010 –0.02 –1.04 to 0.66 8 0.063
Fat SDS-Netherlands 3.14 0.02 to 7.39 11 0.95 0.44 to 9.34 11 0.018 1.23 0.08 to 1.78 7 0.116
Lean SDS-US –1.61 –2.81 to 0.17 12 –1.25 –2.51 to 2.10 12 0.021 –1.61 –3.26 to 0.77 8 0.735
Lean SDS-Netherlands –2.95 –5.35 to 1.50 11 –1.79 –4.69 to 0.17 11 0.005 –1.33 –3.50 to –0.66 7 0.028
Data are given as standard deviation scores adjusted for age and sex (SDS-Netherlands), or basing on prediction models (SDS-US);
SDS-US for lean mass is additionally corrected for height.
* Level of significance versus values before therapy.
until 24 months of therapy, and then stabilized, the
decrease being greatest during the first 6 months (fig. 2)
and in prepubertal children, namely 0.76 SD, range –1.7
to 3.0 after 42 months. Detailed data are provided else-
where [9].
Body Composition
In all patients classified as ‘overweight’ based on WfH
SDS 10, the percentage of body fat was in fact distinctive-
ly elevated (table 2) above the normal range for age-
matched children [14], and even for adults (12–28% in
males, 15–30% in females). During 42 months of GH
therapy, the percentage of fat significantly decreased, as
did WfH, but remained slightly elevated. This result,
however, in part is conditioned by the deficit of LBM (see
below).
Since in PWS, both the compartments of fat mass and
of LBM have been described to be adversely affected, they
have to be assessed separately and not only in relation to
total body mass. For that reason, results are indicated as
longitudinal individual courses (fig. 3) of fat SD scores
adjusted for age and sex; the correction for height did not
change the average results of fat mass and is therefore not
shown. Fat mass SDS dropped during GH therapy
(table 2, fig. 3), more so during the first 6–12 months
(table 2), and was stabilized around the normal mean
thereafter. In prepubertal patients, fat mass remained sig-
nificantly below the initial fat mass until 42 months (ta-
ble 2). The higher the initial weight, the more fat mass was
lost during GH therapy (fig. 3). In some patients, fat mass
slightly increased again after 2 years of treatment (fig. 3),
but remained in the normal range. Yet the elevation of fat
SDS in the overweight patients before therapy was less
clear than suggested by the percentage of fat; we assumed
Fig. 3. Total fat mass measured by DEXA in 12 children with PWS,
as SD scores corrected for age and sex based on a prediction model,
compared to US American children (see Methods); individual
courses before and under therapy with GH in young underweight
(group 1, triangles), prepubertal overweight (group 2, squares), and
pubertal PWS children (group 3, diamonds, dotted lines). Top: boys,
bottom: girls.
that this reflects the increasing adiposity of the US Ameri-
can reference population which impedes the delineation
of obesity in PWS. Consequently, we also compared the
PWS values to Western European references [14]. These
data reveal (table 2) that fat mass is clearly increased in
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Fig. 4. Lean tissue mass in 12 children with PWS measured by
DEXA as SD scores based on a prediction model corrected for
height, age and sex, compared to US American children. Top: boys,
bottom: girls (symbols as indicated in figure 3).
PWS children when compared to age-matched healthy
Dutch children of the same sex. In addition, the pattern of
fat loss and the decrease of fat mass by about 2 SD during
GH therapy are identical to the changes described by
relating the data to US references.
LTM adjusted for height and age (fig. 4) before therapy
was reduced to the lower limit of US references in prepu-
bertal PWS children 15 years (fig. 4), but less reduced in
the pubertal patients. However, there was no significant
increase of lean mass beyond the first 6 months of therapy
(fig. 4, table 2). When compared to the Dutch references,
the deficit of lean mass was more evident, and also greater
in the prepubertal overweight than in the pubertal pa-
tients. The results before therapy were substantially the
same, irrespective of adjusting for age or height. During
GH treatment, a significant increase of LTM was ob-
served in prepubertal and pubertal children, when adjust-
ing for age, though remaining subnormal, with a maxi-
mum gain of LTM reached after 6–12 months (table 2).
However, when LTM was adjusted for height (data not
shown), there was no longer any significant increase of
lean mass beyond the first 6 months, similar to the results
obtained with the US reference data. This discrepancy
shows that the increase of lean mass reflects the growth-
related increase of lean mass, but not a catch-up of the
initial deficit of lean tissue – e.g. muscle mass.
The groups were too small to reveal any sex difference
of body composition before or during GH therapy in
PWS.
Discussion
We report on 12 children with PWS treated with GH
during 3.5 years on average. Height in the prepubertal
overweight children markedly improved, illustrating that
in PWS, the sensitivity to the anabolic effects of GH on
growth is not impaired. All overweight children showed a
marked and continuous decrease of WfH and, provided
treatment had been started before onset of puberty, no
longer presented either the obese phenotype or short sta-
ture. Thus two major PWS features were no longer
present after 3 years of GH treatment in this age group.
Until now, a significant weight loss has been shown only
in studies up to 24 months of GH therapy [17, 18].
The present study aimed at separately analyzing abso-
lute fat and lean mass in relation to normative data and
was thereby faced with several difficulties: First, body
composition in children !6 years is measured in only very
few studies. We therefore were obliged to accept either a
reference group examined by the same DEXA system, but
in a US American population with a 2- to 3-fold higher
incidence of obesity [19–21], or with an appropriate pop-
ulation (The Netherlands) measured with a different
DEXA instrument [14]. Secondly, the reduced height
before GH therapy and the catch-up growth during treat-
ment required to adjust the data not only for age and sex,
but also for height.
As argued above, the increased fat mass in PWS chil-
dren is less evident in comparison to the American refer-
ence data than in relation to the Dutch data. Nevertheless,
the DEXA examination confirms a net reduction of body
fat during GH therapy in the prepubertal and pubertal
overweight children, with a minimum of body fat mass
reached at the end of the second year of treatment. The
significant decrease of fat mass after 1 year of therapy has
also been shown in several controlled [4, 5] and uncon-
trolled studies [7, 8]. In one controlled study [22], how-
ever, weight, BMI and skin folds were not significantly
reduced after 1 year of GH therapy, probably because
dietary intake was not considered. Studies in obese adults
have shown that GH has a clear fat-reducing effect only if
dietary intake is modestly reduced or kept constant, and if
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
22
/2
01
6 
2:
11
:1
9 
PM
Body Composition under Long-Term GH
Therapy in PWS
Horm Res 2000;53:200–206 205
doses from 0.01 to a maximum of 0.05 mg GH/kg/day are
administered [23–26].
In the present paper, as well as in two recently published
studies [27, 28], the lipolytic GH effect seems to diminish
in the long term. As extrapolated from studies in children
with GH deficiency, intrauterine growth retardation or
Turner’s syndrome and in healthy obese adults, the net
effects of GH on body composition, induced by lipolysis
and protein anabolism, are limited to several weeks [29] or
months [30, 31]. It is therefore nevertheless remarkable
that GH induces sustained metabolic effects in obese chil-
dren with PWS. While the metabolic effects of GH are
reported to be independent of prior GH secretion [31], it
nevertheless has to be pointed out that the dose dependen-
cy of the effects of GH on muscular and fat tissue has not
yet been investigated in children. The doses used in the
PWS studies in general are between 0.03 and 0.04 mg/kg/
day, that is 1.5-fold of that administered for substitution in
GH deficiency [32]. We also speculate that the fat rebound
results from an increased food intake: the monitoring of
the diet might be less restrictive due to the parents’ emo-
tional relief in view of the weight normalization during GH
therapy. This might not be correctly reflected by dietary
protocols, which showed an energy intake reduced by at
least 20% compared to healthy children. Further studies on
the balance of energy metabolism in PWS and parental
educational behavior are being conducted.
PWS patients can store fat with a smaller gain of fat-free
mass [33] compared to healthy obese children; the reduc-
tion of lean mass in spite of obesity [1] has been attributed
to the hypothalamic GH deficiency in PWS [34]. In fact, in
the present study, a marked decrease of lean mass was doc-
umented before therapy, in comparison to the Dutch refer-
ence children, but this deficit of LTM was smaller in com-
parison to American children. In the pubertal patients, the
less reduced lean mass before therapy and the subsequent
increase might be overlapped by the additional effect of
endogenous and exogenous androgens.
Several studies [4, 5, 7], including our own [6], have
demonstrated that lean mass increases after 1 year of GH
therapy. Provided the data are related to age only, this
remains so even after 3.5 years. This study is the first to
show, however, that no long-term additional gain of mus-
cle mass beyond the first year was achieved by GH thera-
py, when lean mass is corrected for its growth-related
increase. In contrast to what could be concluded from ba-
sal studies [34] or 1-year GH treatments [4–7], GH therapy
not even in the long term compensated for the initial defi-
cit of lean mass. This matches the observations in chil-
dren with and without GH deficiency under GH therapy
[30, 31], where muscle catch-up growth was maintained
only during the first 6–12 months and then returned to a
steady state. We conclude that GH alone – at least in the
dosage administered – is not sufficient to normalize lean
body mass; even under 10 years of GH substitution in
GH-deficient adults, a substantial lack of lean mass com-
pared to healthy controls has been reported recently [35].
It is evident that any growth of muscles, the main constit-
uent of LTM, depends on physical training and not on
hormones alone. Therefore, the initial approach to im-
prove muscle mass in PWS by GH therapy solely was
somewhat mistaken, even though a – still insufficient –
increase of physical activity has been described [4, 6].
This might be the main clue in PWS: physical inactivity
and muscle hypotonia, probably induced by a defective
CNS regulation, result in decreased muscle mass and
reduced energy turnover, and finally lead to obesity,
which is enhanced by additional hypothalamic defects of
appetite regulation and GH secretion. We therefore sug-
gest that a comprehensive care for PWS children has to
combine GH substitution with a reduction of energy
intake and physical exercise to provide for an efficacious
treatment of the somatic deficits of this syndrome. The
mental retardation and the compulsive behavior disorder,
however, will remain major handicaps.
In conclusion, exogenous GH changes the phenotype
of PWS in childhood: height and weight become normal
and there is a sustained impact on the net loss of body fat,
which nevertheless remains slightly elevated. The long-
term effects of exogenous GH on muscle anabolism in
PWS are less marked than extrapolated from the observa-
tions under the first year of therapy and do not exceed the
height-related growth. After 2 years of therapy, there
seems to be a loss of sensitivity to the metabolic, but not to
the growth-promoting GH effects. In addition to the med-
ical benefit, the disappearance of the obese phenotype of
prepubertally GH-treated PWS children relieves the pa-
tients and their families of stigmatization.
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